On February 14, 2020 The Board of Oasmia Pharmaceutical reported that has appointed Francois Martelet as the new CEO (Press release, Oasmia, FEB 14, 2020, View Source [SID1234556575]). Dr Martelet has extensive international experience of leading pharmaceutical companies. He replaces Sven Rohmann, who has been acting CEO during a crucial transition period. Mr Rohmann remains in his position as Board member and will continue to play an active role in the company’s commercialization strategy going forward.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Francois Martelet is an experienced Pharma executive with a proven track record of shaping companies and turning around underperforming units. He has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive roles at senior level at Roche, Eli Lilly, Novartis and MSD. He has been based in six countries in Europe (including Sweden) and in the US. Francois Martelet is a French Medical Doctor, with a Masters Degree in Business. He speaks four languages, among them Swedish. Dr Martelet will take up his position on March 15, 2020.